The present study estimated the population pharmacokinetics of lamotrigine
in patients receiving oral lamotrigine therapy with drug concentration moni
toring, and determined intersubject and intrasubject variability. A total o
f 129 patients were analyzed from two clinical sites. Of these, 124 patient
s provided spare data (198 concentration-time points); nine patients (four
from a previous group plus five from the current group) provided rich data
(431 points). The population analysis was conducted using P-PHARM (TM) (SIM
ED Scientific Software, Cedex, France), a nonlinear mixed-effect modeling p
rogram. A single exponential elimination model (first-order absorption) wit
h heteroscedastic weighting was used. Apparent clearance (CL/F) and volume
of distribution (V/F) were the pharmacokinetic parameters estimated. Covari
ate analysis was performed to determine which factors explained any of the
variability associated with lamotrigine clearance. Population estimates of
CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.8
1 L/h and 78.1 +/- 5.1 L/kg. Intersubject and intrasubject variability for
clearance was 38% and 38%, respectively. The covariates of concomitant valp
roate and phenytoin therapy accounted for 42% of the intersubject variabili
ty of clearance. Age, gender, clinic site, and other concomitant antiepilep
tic drugs did not influence clearance. This study of the population pharmac
okinetics of lamotrigine in patients using the drug clinically provides use
ful data and should lead to better dosage individualization for lamotrigine
.